A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2018
At a glance
- Drugs ERY-ASP (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRYbeCA-1
- Sponsors ERYtech Pharma
- 15 Nov 2018 According to an ERYtech Pharma media release, the company has a red blood cell supply and research partnership with New York Blood Center (NYBC) for this and other trial (see profile 293090). The company is planning to begin enrollment in the United States early in 2019.
- 12 Nov 2018 According to an ERYtech Pharma media release, an interim analysis is foreseen when approximately two-thirds of events have occurred.
- 20 Sep 2018 According to an ERYtech Pharma media release, Status changed from not yet recruiting to recruiting.